Iinvest,

I believe that was you who mentioned that there is a sort of disconnect in this arena.

1.A person such as Cat or anyone who has been told that some irregularity exists in an exam is 150% interested in the results. They don't want to hear," Well it is a bit irregular....lets keep an eye on it" They want some closure today.

On the same note, a person who has been treated for cancer wants to know it is still absent. Today ...next week ...next month...next year. Each person will have his or her interval in time with regard to knowing it has not resurfaced. This interest is again at 150%.

The other side of the coin is the person who is given a clean bill of health. Never had cancer and is supposedly provided with another good check up. If a cancer is missed, they didn't know any different anyway. They will forget about the test in a few days. Interest equals say 30%. If cancer or symtoms appear at a later date for this person then the interest in Recaf shoots from 30% to the 150% immediately.

When a friend gets cancer, those around that person begin to reflect on their personal chances of getting the same. Or a small lump or growth (sometimes even a pimple) are discovered...Again that Recaf interest peaks.

People will pay top dollar for that 150% interest. A Diagnostic company tends to have an eye on a product such as this. It is instant gratification and that is what sells! Along with mandated tests and the favorite ordered doctor's tests (PSA, PAP, MRI, Mammograms etc)

Instant tests such as the pregnancy test, instant diabetic tests, instant step tests, and especially instant cancer tests. There is tremendous money involved in these. We know that Inverness wanted to complement Matritech and Diamics from the words out of the mouth of the VP of Oncology. Dr. Moro explained that we will see this within a year. That has to mean that Inverness is ready for FDA testing as that process is about 8 months + / - .

It is tough to wait it out. But this is also a test that truelly trumps all others.

RECAF technology complements the recent acquisition of Matritech and the equity investment in Diamics and should enhance our product development efforts in these areas,” said Ferran Prat, VP of Oncology for Inverness Medical Innovations. “As only the second diagnostic manufacturer with access to RECAF, this agreement represents an important competitive step for Inverness within the oncology diagnostics and monitoring markets.”

Notice it states, "oncology diagnostics and monitoring markets"